Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 5/2007

01-10-2007 | Original Article

Weekday on-weekend off oral capecitabine: a phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy

Authors: G. Pentheroudakis, P. Pappas, V. Golfinopoulos, G. Fountzilas, M. Nikolaidou, V. A. Boumba, T. Vougiouklakis, L. Nikiforidis, E. Tzamakou, O. Siarabi, M. Marselos, N. Pavlidis

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2007

Login to get access

Abstract

Background

Although protracted intravenous 5-fluorouracil is superior to bolus regimens in terms of tumour exposure to the drug during DNA synthesis as well as activity and safety, the oral fluoropyrimidine capecitabine is administered intermittently. In this phase I study, we investigated an alternative, dose-intense continuous regimen.

Materials and methods

Oral capecitabine was administered twice daily continuously with weekend breaks, in patients with advanced solid tumours refractory to standard therapy. Dose escalation proceeded from 1,331 to 2,510 mg/m2 daily. Dose limiting toxicity (DLT) consisted of any grade-3 or 4 adverse event except for alopecia and skin toxicity resolving within 7 days.

Results

Twenty-five heavily pretreated patients participated in the study. No DLT occurred in the first four cohorts. Two out of four patients developed grade III diarrhoea in the fourth week of capecitabine at 2,510 mg/m2 (DLT). The most common toxic episodes during all cycles of treatment were grade 1–2 fatigue, skin erythema, abdominal cramps, nausea, constipation and neutropenia. Disease regression was seen in three and stabilisation with clinical benefit in ten patients (clinical benefit response 54%). Pharmacokinetic studies of capecitabine and metabolites in four patients at 2,250 mg/m2 daily showed rapid absorption, short plasma half-lives with the exception of FBAL and absence of accumulation or conversion saturation during the course of therapy. At this dose, administered dose intensity in eight patients was 99.3% of the planned one.

Conclusions

Weekday on-weekend off capecitabine maximizes cytotoxic impact on tumour cells during S-phase by safely simulating protracted fluoropyrimidine therapy at a recommended dose (2,250 mg/m2) close to that of the intermittent schedule and clearly higher than the continuous one of 1,331 mg/m2.
Literature
1.
go back to reference Presant CA, Wolf W, Albright MJ, Servis KL, Ring R et al. (1990) Human tumour fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics. J Clin Oncol 8:1868–1873PubMed Presant CA, Wolf W, Albright MJ, Servis KL, Ring R et al. (1990) Human tumour fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics. J Clin Oncol 8:1868–1873PubMed
2.
go back to reference Peters GJ, Lankelma J, Kok RM, Noordhuis P, van Groeningen CJ et al. (1993) Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumours as compared with plasma. Cancer Chemother Pharmacol 31:269–276PubMedCrossRef Peters GJ, Lankelma J, Kok RM, Noordhuis P, van Groeningen CJ et al. (1993) Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumours as compared with plasma. Cancer Chemother Pharmacol 31:269–276PubMedCrossRef
3.
go back to reference Thomas CM, Zalcberg JR (1998) 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin Exp Pharmacol Physiol 25:887–895PubMedCrossRef Thomas CM, Zalcberg JR (1998) 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin Exp Pharmacol Physiol 25:887–895PubMedCrossRef
4.
go back to reference Meta-Analysis Group in Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301–308 Meta-Analysis Group in Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301–308
5.
go back to reference De Gramont A, Bosset JF, Milan C et al. (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15:808–815PubMed De Gramont A, Bosset JF, Milan C et al. (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15:808–815PubMed
6.
go back to reference Pentheroudakis G, Twelves C (2002) The rational development of capecitabine from the laboratory to the clinic. Anticancer Res 22:3589–3596PubMed Pentheroudakis G, Twelves C (2002) The rational development of capecitabine from the laboratory to the clinic. Anticancer Res 22:3589–3596PubMed
7.
go back to reference Van Cutsem E, Findlay M, Osterwalder B et al. (2000) Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 18:1337–1345PubMed Van Cutsem E, Findlay M, Osterwalder B et al. (2000) Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 18:1337–1345PubMed
8.
9.
go back to reference Evans TR, Pentheroudakis G, Paul J et al. (2002) A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. Ann Oncol 13:1469–1478PubMedCrossRef Evans TR, Pentheroudakis G, Paul J et al. (2002) A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. Ann Oncol 13:1469–1478PubMedCrossRef
10.
go back to reference Anderson D, Kerr DJ, Blesing C et al. (1997) Simultaneous gas chromatographic-mass spectrophotometric determination of alpha-fluoro-beta-alanine and 5-fluorouracil in plasma. J Chromatogr B Biomed Sci Appl 688:87–93PubMedCrossRef Anderson D, Kerr DJ, Blesing C et al. (1997) Simultaneous gas chromatographic-mass spectrophotometric determination of alpha-fluoro-beta-alanine and 5-fluorouracil in plasma. J Chromatogr B Biomed Sci Appl 688:87–93PubMedCrossRef
11.
12.
go back to reference The Meta-analysis Group in Cancer (2004) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 22:3766–3775CrossRef The Meta-analysis Group in Cancer (2004) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 22:3766–3775CrossRef
13.
go back to reference Mackean M, Planting A, Twelves C et al. (1998) Phase I and pharmacologic study of intermittent twice daily oral therapy with capecitabine in patients with advanced or metastatic cancer. J Clin Oncol 16:2977–2985PubMed Mackean M, Planting A, Twelves C et al. (1998) Phase I and pharmacologic study of intermittent twice daily oral therapy with capecitabine in patients with advanced or metastatic cancer. J Clin Oncol 16:2977–2985PubMed
14.
go back to reference Budman DR, Meropol NJ, Reigner B et al. (1998) Preliminary studies of a novel oral fluoropyrimidine carbamate, capecitabine. J Clin Oncol 16:1795–1802PubMed Budman DR, Meropol NJ, Reigner B et al. (1998) Preliminary studies of a novel oral fluoropyrimidine carbamate, capecitabine. J Clin Oncol 16:1795–1802PubMed
15.
go back to reference Tebbutt NC, Norman AR, Cunningham D, Allen M, Chau I et al. (2003) Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil. Br J Cancer 88:1510–1515PubMedCrossRef Tebbutt NC, Norman AR, Cunningham D, Allen M, Chau I et al. (2003) Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil. Br J Cancer 88:1510–1515PubMedCrossRef
16.
go back to reference Ishikawa T, Utoh M, Sawada N et al. (1998) Tumour selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55:1091–1097PubMedCrossRef Ishikawa T, Utoh M, Sawada N et al. (1998) Tumour selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55:1091–1097PubMedCrossRef
17.
go back to reference Reigner B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40:85–104PubMedCrossRef Reigner B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40:85–104PubMedCrossRef
18.
go back to reference Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, et al. (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38:349–358PubMedCrossRef Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, et al. (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38:349–358PubMedCrossRef
19.
go back to reference Pentheroudakis G, Twelves C (2002) Capecitabine (Xeloda): from the laboratory to the patient’s home. Clin Colorectal Cancer 2:16–23PubMedCrossRef Pentheroudakis G, Twelves C (2002) Capecitabine (Xeloda): from the laboratory to the patient’s home. Clin Colorectal Cancer 2:16–23PubMedCrossRef
20.
go back to reference Pinedo HM, Peters GFJ (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653–1664PubMed Pinedo HM, Peters GFJ (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653–1664PubMed
21.
go back to reference Gieschke R, Reigner B, Blesch KS, Steimer JL (2002) Population pharmacokinetic analysis of the major metabolites of capecitabine. J Pharmacokinet Pharmacodynam 29:25–47CrossRef Gieschke R, Reigner B, Blesch KS, Steimer JL (2002) Population pharmacokinetic analysis of the major metabolites of capecitabine. J Pharmacokinet Pharmacodynam 29:25–47CrossRef
22.
go back to reference Ngan SY, Michael M, Mackay J et al. (2004) A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer. Br J Cancer 91:1019–1024PubMed Ngan SY, Michael M, Mackay J et al. (2004) A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer. Br J Cancer 91:1019–1024PubMed
23.
go back to reference Machiels JPP, Duck L, Honhon B et al. (2005) Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with locally advanced rectal adenocarcinoma: The RadioOxCape study. Proc Am Soc Clin Oncol GI (abstr 245) Machiels JPP, Duck L, Honhon B et al. (2005) Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with locally advanced rectal adenocarcinoma: The RadioOxCape study. Proc Am Soc Clin Oncol GI (abstr 245)
Metadata
Title
Weekday on-weekend off oral capecitabine: a phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy
Authors
G. Pentheroudakis
P. Pappas
V. Golfinopoulos
G. Fountzilas
M. Nikolaidou
V. A. Boumba
T. Vougiouklakis
L. Nikiforidis
E. Tzamakou
O. Siarabi
M. Marselos
N. Pavlidis
Publication date
01-10-2007
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2007
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-007-0419-6

Other articles of this Issue 5/2007

Cancer Chemotherapy and Pharmacology 5/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine